News

October 2011 – Buccolam granted first PUMA

Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures

Sale of Interest in Product

Therakind Limited (“Therakind”), a paediatric healthcare company, is pleased to report that it has sold the majority of its interest in midazolam hydrochloride oromucosal solution, a product which has been designed for the rapid treatment of children suffering from acute epileptic seizures.

Therakind Walkathon 2010

On 9 March 2010, we completed a sponsored walk in support of Epilepsy Research.

There are 60,000 children in the UK who suffer with epilepsy. We achieved our challenge to walk 60,000 steps (~26 miles) for those 60,000 children and raised a grand total over £6,000.

Many thanks to all who supported us in this worthwhile cause!

In particular, many thanks to our corporate sponsors, Rosemount Pharmaceuticals and Auralis Ltd.

 

The Therakind Team

October 2009 - Clinical Trial for Buccolam

This clinical study, sponsored by Therakind, was initiated in Germany in October 2009 and the authorised product is expected to be available in 2011.

Clinical Trial for Buccolam (PDF)

For further information, please contact us.

April 2009 - Successful Fundraising

Therakind Limited (“Therakind” or the “Company”), a paediatric healthcare business, is delighted to announce that it has successfully raised £350,000 from new investors. Therakind is a spin-out from The School of Pharmacy, University of London and was established in October 2006.

Therakind specialises in paediatric medicine and has the expertise to develop a drug from an idea through to regulatory approval. It develops licensed paediatric medicines in collaboration with partners and benefits from the EU paediatric drug legislation.